{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T12:51:06Z","timestamp":1775134266691,"version":"3.50.1"},"reference-count":109,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T00:00:00Z","timestamp":1720051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T00:00:00Z","timestamp":1720051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100020206","name":"Health Commission of Shandong Province","doi-asserted-by":"publisher","award":["2021M201"],"award-info":[{"award-number":["2021M201"]}],"id":[{"id":"10.13039\/501100020206","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s43440-024-00569-6","type":"journal-article","created":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T16:02:33Z","timestamp":1720108953000},"page":"780-792","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Advances in the anti-tumor mechanisms of saikosaponin D"],"prefix":"10.1007","volume":"76","author":[{"given":"Ruixue","family":"Jia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dandan","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7674-2638","authenticated-orcid":false,"given":"Wei","family":"Geng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,4]]},"reference":[{"issue":"3","key":"569_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"569_CR2","doi-asserted-by":"publisher","first-page":"283","DOI":"10.5582\/bst.2021.01318","volume":"15","author":"X Zhang","year":"2021","unstructured":"Zhang X, Qiu H, Li C, Cai P, Qi F. The positive role of traditional Chinese medicine as an adjunctive therapy for cancer. Biosci Trends. 2021;15(5):283\u201398. https:\/\/doi.org\/10.5582\/bst.2021.01318.","journal-title":"Biosci Trends"},{"issue":"17","key":"569_CR3","first-page":"298","volume":"17","author":"Y Huang","year":"2011","unstructured":"Huang Y, Huang W, Sun R. Research development on pharmacological effects and hepatotoxicity of bupleurum saikosaponin. Chin J Exp Tradit Med Formulae. 2011;17(17):298\u2013301.","journal-title":"Chin J Exp Tradit Med Formulae"},{"key":"569_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/molecules24132365","author":"Y He","year":"2019","unstructured":"He Y, Hu Z, Li A, Zhu Z, Yang N, Ying Z, He J, Wang C, Yin S, Cheng S. Recent advances in biotransformation of saponins. Molecules. 2019. https:\/\/doi.org\/10.3390\/molecules24132365.","journal-title":"Molecules"},{"issue":"1","key":"569_CR5","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1080\/13880209.2016.1262433","volume":"55","author":"B Yuan","year":"2017","unstructured":"Yuan B, Yang R, Ma Y, Zhou S, Zhang X, Liu Y. A systematic review of the active saikosaponins and extracts isolated from Radix Bupleuri and their applications. Pharm Biol. 2017;55(1):620\u201335. https:\/\/doi.org\/10.1080\/13880209.2016.1262433.","journal-title":"Pharm Biol"},{"issue":"5","key":"569_CR6","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.3892\/mmr.2014.2574","volume":"10","author":"S He","year":"2014","unstructured":"He S, Lu G, Hou H, Zhao Z, Zhu Z, Lu X, Chen J, Wang Z. Saikosaponin-d suppresses the expression of cyclooxygenase-2 through the phospho-signal transducer and activator of transcription 3\/hypoxia-inducible factor-1\u03b1 pathway in hepatocellular carcinoma cells. Mol Med Rep. 2014;10(5):2556\u201362. https:\/\/doi.org\/10.3892\/mmr.2014.2574.","journal-title":"Mol Med Rep"},{"issue":"2","key":"569_CR7","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.canlet.2004.03.044","volume":"213","author":"YL Hsu","year":"2004","unstructured":"Hsu YL, Kuo PL, Chiang LC, Lin CC. Involvement of p53, nuclear factor kappaB and Fas\/Fas ligand in induction of apoptosis and cell cycle arrest by saikosaponin D in human hepatoma cell lines. Cancer Lett. 2004;213(2):213\u201321. https:\/\/doi.org\/10.1016\/j.canlet.2004.03.044.","journal-title":"Cancer Lett"},{"issue":"10","key":"569_CR8","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.lfs.2004.03.008","volume":"75","author":"YL Hsu","year":"2004","unstructured":"Hsu YL, Kuo PL, Lin CC. The proliferative inhibition and apoptotic mechanism of saikosaponin D in human non-small cell lung cancer A549 cells. Life Sci. 2004;75(10):1231\u201342. https:\/\/doi.org\/10.1016\/j.lfs.2004.03.008.","journal-title":"Life Sci"},{"issue":"11","key":"569_CR9","doi-asserted-by":"publisher","first-page":"4974","DOI":"10.1021\/acs.molpharmaceut.8b00595","volume":"15","author":"X Chen","year":"2018","unstructured":"Chen X, Liu C, Zhao R, Zhao P, Wu J, Zhou N, Ying M. Synergetic and antagonistic molecular effects mediated by the feedback loop of p53 and JNK between saikosaponins D and SP600125 on lung cancer A549 cells. Mol Pharm. 2018;15(11):4974\u201384. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.8b00595.","journal-title":"Mol Pharm"},{"issue":"2","key":"569_CR10","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.3892\/mmr.2017.6765","volume":"16","author":"Y Li","year":"2017","unstructured":"Li Y, Cai T, Zhang W, Zhu W, Lv S. Effects of Saikosaponins D on apoptosis in human U87 glioblastoma cells. Mol Med Rep. 2017;16(2):1459\u201364. https:\/\/doi.org\/10.3892\/mmr.2017.6765.","journal-title":"Mol Med Rep"},{"issue":"59","key":"569_CR11","doi-asserted-by":"publisher","first-page":"99825","DOI":"10.18632\/oncotarget.21076","volume":"8","author":"H Tsuyoshi","year":"2017","unstructured":"Tsuyoshi H, Wong VKW, Han Y, Orisaka M, Yoshida Y, Tsang BK. Saikosaponin-d, a calcium mobilizing agent, sensitizes chemoresistant ovarian cancer cells to cisplatin-induced apoptosis by facilitating mitochondrial fission and G2\/M arrest. Oncotarget. 2017;8(59):99825\u201340. https:\/\/doi.org\/10.18632\/oncotarget.21076.","journal-title":"Oncotarget"},{"key":"569_CR12","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.biopha.2018.09.038","volume":"108","author":"J Wang","year":"2018","unstructured":"Wang J, Qi H, Zhang X, Si W, Xu F, Hou T, Zhou H, Wang A, Li G, Liu Y, Fang Y, Piao HL, Liang X. Saikosaponin D from Radix Bupleuri suppresses triple-negative breast cancer cell growth by targeting \u03b2-catenin signaling. Biomed Pharmacother. 2018;108:724\u201333. https:\/\/doi.org\/10.1016\/j.biopha.2018.09.038.","journal-title":"Biomed Pharmacother"},{"issue":"7","key":"569_CR13","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.prp.2017.01.022","volume":"213","author":"C Li","year":"2017","unstructured":"Li C, Guan X, Xue H, Wang P, Wang M, Gai X. Reversal of P-glycoprotein-mediated multidrug resistance is induced by Saikosaponins D in breast cancer MCF-7\/adriamycin cells. Pathol Res Pract. 2017;213(7):848\u201353. https:\/\/doi.org\/10.1016\/j.prp.2017.01.022.","journal-title":"Pathol Res Pract"},{"issue":"19","key":"569_CR14","first-page":"4437","volume":"21","author":"C Li","year":"2017","unstructured":"Li C, Xue HG, Feng LJ, Wang ML, Wang P, Gai XD. The effect of Saikosaponins D on doxorubicin pharmacokinetics and its MDR reversal in MCF-7\/adr cell xenografts. Eur Rev Med Pharmacol Sci. 2017;21(19):4437\u201345.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"8","key":"569_CR15","doi-asserted-by":"publisher","first-page":"5512","DOI":"10.1002\/jcp.30276","volume":"236","author":"M Vaghari-Tabari","year":"2021","unstructured":"Vaghari-Tabari M, Ferns GA, Qujeq D, Andevari AN, Sabahi Z, Moein S. Signaling, metabolism, and cancer: an important relationship for therapeutic intervention. J Cell Physiol. 2021;236(8):5512\u201332. https:\/\/doi.org\/10.1002\/jcp.30276.","journal-title":"J Cell Physiol"},{"issue":"5","key":"569_CR16","doi-asserted-by":"publisher","first-page":"5683","DOI":"10.1002\/jcp.27411","volume":"234","author":"N Hashemi Goradel","year":"2019","unstructured":"Hashemi Goradel N, Najafi M, Salehi E, Farhood B, Mortezaee K. Cyclooxygenase-2 in cancer: a review. J Cell Physiol. 2019;234(5):5683\u201399. https:\/\/doi.org\/10.1002\/jcp.27411.","journal-title":"J Cell Physiol"},{"issue":"15","key":"569_CR17","doi-asserted-by":"publisher","first-page":"12342","DOI":"10.3390\/ijms241512342","volume":"24","author":"M Coluccia","year":"2023","unstructured":"Coluccia M. Cyclooxygenase and Cancer: Fundamental Molecular Investigations. Int J Mol Sci. 2023;24(15):12342. https:\/\/doi.org\/10.3390\/ijms241512342.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"569_CR18","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1053\/j.gastro.2021.09.059","volume":"161","author":"D Wang","year":"2021","unstructured":"Wang D, Cabalag CS, Clemons NJ, DuBois RN. Cyclooxygenases and prostaglandins in tumor immunology and microenvironment of gastrointestinal cancer. Gastroenterology. 2021;161(6):1813\u201329. https:\/\/doi.org\/10.1053\/j.gastro.2021.09.059.","journal-title":"Gastroenterology"},{"issue":"5","key":"569_CR19","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.3892\/ijo.2020.5013","volume":"56","author":"TJ Collard","year":"2020","unstructured":"Collard TJ, Fallatah HM, Greenhough A, Paraskeva C, Williams AC. BCL-3 promotes cyclooxygenase-2\/prostaglandin E2 signalling in colorectal cancer. Int J Oncol. 2020;56(5):1304\u201313. https:\/\/doi.org\/10.3892\/ijo.2020.5013.","journal-title":"Int J Oncol"},{"issue":"13","key":"569_CR20","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.7150\/ijbs.35128","volume":"15","author":"ZZ Lai","year":"2019","unstructured":"Lai ZZ, Yang HL, Ha SY, Chang KK, Mei J, Zhou WJ, Qiu XM, Wang XQ, Zhu R, Li DJ, Li MQ. Cyclooxygenase-2 in Endometriosis. Int J Biol Sci. 2019;15(13):2783\u201397. https:\/\/doi.org\/10.7150\/ijbs.35128.","journal-title":"Int J Biol Sci"},{"issue":"28","key":"569_CR21","doi-asserted-by":"publisher","first-page":"4653","DOI":"10.3748\/wjg.v27.i28.4653","volume":"27","author":"XK Ji","year":"2021","unstructured":"Ji XK, Madhurapantula SV, He G, Wang KY, Song CH, Zhang JY, Wang KJ. Genetic variant of cyclooxygenase-2 in gastric cancer: more inflammation and susceptibility. World J Gastroenterol. 2021;27(28):4653\u201366. https:\/\/doi.org\/10.3748\/wjg.v27.i28.4653.","journal-title":"World J Gastroenterol"},{"issue":"6","key":"569_CR22","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1158\/1940-6207.CAPR-22-0038","volume":"15","author":"DJ Wilson","year":"2022","unstructured":"Wilson DJ, DuBois RN. Role of prostaglandin E2 in the progression of gastrointestinal cancer. Cancer Prev Res (Philadelphia, PA). 2022;15(6):355\u201363. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-22-0038.","journal-title":"Cancer Prev Res (Philadelphia, PA)"},{"issue":"6","key":"569_CR23","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1007\/s00404-020-05559-6","volume":"301","author":"Y Ye","year":"2020","unstructured":"Ye Y, Wang X, Jeschke U, von Sch\u00f6nfeldt V. COX-2-PGE2-EPs in gynecological cancers. Arch Gynecol Obstet. 2020;301(6):1365\u201375. https:\/\/doi.org\/10.1007\/s00404-020-05559-6.","journal-title":"Arch Gynecol Obstet"},{"key":"569_CR24","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/bs.apcsb.2019.09.004","volume":"119","author":"R Khandia","year":"2020","unstructured":"Khandia R, Munjal A. Interplay between inflammation and cancer. Adv Protein Chem Struct Biol. 2020;119:199\u2013245. https:\/\/doi.org\/10.1016\/bs.apcsb.2019.09.004.","journal-title":"Adv Protein Chem Struct Biol"},{"issue":"18","key":"569_CR25","doi-asserted-by":"publisher","first-page":"3622","DOI":"10.2174\/0929867327999200917150939","volume":"28","author":"J Cui","year":"2021","unstructured":"Cui J, Jia J. Natural COX-2 inhibitors as promising anti-inflammatory agents: an update. Curr Med Chem. 2021;28(18):3622\u201346. https:\/\/doi.org\/10.2174\/0929867327999200917150939.","journal-title":"Curr Med Chem"},{"key":"569_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.prostaglandins.2019.106338","volume":"144","author":"V Karpisheh","year":"2019","unstructured":"Karpisheh V, Nikkhoo A, Hojjat-Farsangi M, Namdar A, Azizi G, Ghalamfarsa G, Sabz G, Yousefi M, Yousefi B, Jadidi-Niaragh F. Prostaglandin E2 as a potent therapeutic target for treatment of colon cancer. Prostaglandins Other Lipid Mediat. 2019;144: 106338. https:\/\/doi.org\/10.1016\/j.prostaglandins.2019.106338.","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"569_CR27","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/215158","author":"C Sobolewski","year":"2010","unstructured":"Sobolewski C, Cerella C, Dicato M, Ghibelli L, Diederich M. The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies. Int J Cell Biol. 2010. https:\/\/doi.org\/10.1155\/2010\/215158.","journal-title":"Int J Cell Biol"},{"issue":"23","key":"569_CR28","doi-asserted-by":"publisher","first-page":"6798","DOI":"10.1046\/j.1432-1033.2000.01778.x","volume":"267","author":"B Thomas","year":"2000","unstructured":"Thomas B, Berenbaum F, Humbert L, Bian H, B\u00e9r\u00e9ziat G, Crofford L, Olivier JL. Critical role of C\/EBPdelta and C\/EBPbeta factors in the stimulation of the cyclooxygenase-2 gene transcription by interleukin-1beta in articular chondrocytes. Eur J Biochem. 2000;267(23):6798\u2013809. https:\/\/doi.org\/10.1046\/j.1432-1033.2000.01778.x.","journal-title":"Eur J Biochem"},{"issue":"2","key":"569_CR29","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1165\/rcmb.2005-0154OC","volume":"35","author":"GY Suh","year":"2006","unstructured":"Suh GY, Jin Y, Yi AK, Wang XM, Choi AM. CCAAT\/enhancer-binding protein mediates carbon monoxide-induced suppression of cyclooxygenase-2. Am J Respir Cell Mol Biol. 2006;35(2):220\u20136. https:\/\/doi.org\/10.1165\/rcmb.2005-0154OC.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"569_CR30","doi-asserted-by":"publisher","first-page":"623","DOI":"10.3389\/fphar.2019.00623","volume":"10","author":"M Ren","year":"2019","unstructured":"Ren M, McGowan E, Li Y, Zhu X, Lu X, Zhu Z, Lin Y, He S. Saikosaponin-d suppresses COX2 through p-STAT3\/C\/EBP\u03b2 signaling pathway in liver cancer: a novel mechanism of action. Front Pharmacol. 2019;10:623. https:\/\/doi.org\/10.3389\/fphar.2019.00623.","journal-title":"Front Pharmacol"},{"issue":"10","key":"569_CR31","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.3389\/fphar.2019.01039","volume":"2019","author":"CY Zhang","year":"2019","unstructured":"Zhang CY, Jiang ZM, Ma XF, Li Y, Liu XZ, Li LL, Wu WH, Wang T. Saikosaponin-d inhibits the hepatoma cells and enhances chemosensitivity through SENP5-dependent inhibition of Gli1 SUMOylation under hypoxia. Front Pharmacol. 2019;2019(10):1039. https:\/\/doi.org\/10.3389\/fphar.2019.01039.","journal-title":"Front Pharmacol"},{"issue":"9","key":"569_CR32","first-page":"712","volume":"14","author":"SX He","year":"2006","unstructured":"He SX, Luo JY, Zhao G, Xu JL, Wang YL, Fu H, Dong L. Effect of saikosaponins-d on cyclooxygenase-2 expression of human hepatocellular carcinoma cell line SMMC-7721. Zhonghua Gan Zang Bing Za Zhi. 2006;14(9):712\u20134.","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"issue":"2","key":"569_CR33","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.devcel.2008.01.013","volume":"14","author":"A Besson","year":"2008","unstructured":"Besson A, Dowdy SF, Roberts JM. CDK inhibitors: cell cycle regulators and beyond. Dev Cell. 2008;14(2):159\u201369. https:\/\/doi.org\/10.1016\/j.devcel.2008.01.013.","journal-title":"Dev Cell"},{"issue":"11","key":"569_CR34","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1038\/nrc2728","volume":"9","author":"MR Junttila","year":"2009","unstructured":"Junttila MR, Evan GI. p53\u2014a jack of all trades but master of none. Nat Rev Cancer. 2009;9(11):821\u20139. https:\/\/doi.org\/10.1038\/nrc2728.","journal-title":"Nat Rev Cancer"},{"issue":"19","key":"569_CR35","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1038\/onc.2010.42","volume":"29","author":"J Pirngruber","year":"2010","unstructured":"Pirngruber J, Johnsen SA. Induced G1 cell-cycle arrest controls replication-dependent histone mRNA 3\u2019 end processing through p21, NPAT and CDK9. Oncogene. 2010;29(19):2853\u201363. https:\/\/doi.org\/10.1038\/onc.2010.42.","journal-title":"Oncogene"},{"issue":"6","key":"569_CR36","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/nrc2657","volume":"9","author":"T Abbas","year":"2009","unstructured":"Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer. 2009;9(6):400\u201314. https:\/\/doi.org\/10.1038\/nrc2657.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"569_CR37","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3892\/mmr.2014.2153","volume":"10","author":"M Yao","year":"2014","unstructured":"Yao M, Yang J, Cao L, Zhang L, Qu S, Gao H. Saikosaponin-d inhibits proliferation of DU145 human prostate cancer cells by inducing apoptosis and arresting the cell cycle at G0\/G1 phase. Mol Med Rep. 2014;10(1):365\u201372. https:\/\/doi.org\/10.3892\/mmr.2014.2153.","journal-title":"Mol Med Rep"},{"issue":"9","key":"569_CR38","doi-asserted-by":"publisher","first-page":"300060520937163","DOI":"10.1177\/0300060520937163","volume":"48","author":"S Wu","year":"2020","unstructured":"Wu S, Chen W, Liu K, et al. Saikosaponins D inhibits proliferation and induces apoptosis of non-small cell lung cancer cells by inhibiting the STAT3 pathway. J Int Med Res. 2020;48(9):300060520937163.","journal-title":"J Int Med Res"},{"issue":"9791","key":"569_CR39","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/s0140-6736(10)62307-0","volume":"378","author":"A Vincent","year":"2011","unstructured":"Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378(9791):607\u201320. https:\/\/doi.org\/10.1016\/s0140-6736(10)62307-0.","journal-title":"Lancet"},{"key":"569_CR40","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.humpath.2018.11.026","volume":"86","author":"J Lu","year":"2019","unstructured":"Lu J, Zhou L, Yang G, Liang ZY, Zhou WX, You L, Yuan D, Li BQ, Guo JC, Zhao YP. Clinicopathological and prognostic significance of MKK4 and MKK7 in resectable pancreatic ductal adenocarcinoma. Hum Pathol. 2019;86:143\u201354. https:\/\/doi.org\/10.1016\/j.humpath.2018.11.026.","journal-title":"Hum Pathol"},{"issue":"8","key":"569_CR41","doi-asserted-by":"publisher","first-page":"7495","DOI":"10.3390\/ijms24087495","volume":"24","author":"L Katzengruber","year":"2023","unstructured":"Katzengruber L, Sander P, Laufer S. MKK4 inhibitors-recent development status and therapeutic potential. Int J Mol Sci. 2023;24(8):7495. https:\/\/doi.org\/10.3390\/ijms24087495.","journal-title":"Int J Mol Sci"},{"key":"569_CR42","doi-asserted-by":"publisher","first-page":"9465","DOI":"10.2147\/ott.S263322","volume":"13","author":"M Lai","year":"2020","unstructured":"Lai M, Ge Y, Chen M, Sun S, Chen J, Cheng R. Saikosaponins D inhibits proliferation and promotes apoptosis through activation of MKK4-JNK signaling pathway in pancreatic cancer cells. Onco Targets Ther. 2020;13:9465\u201379. https:\/\/doi.org\/10.2147\/ott.S263322.","journal-title":"Onco Targets Ther"},{"issue":"9","key":"569_CR43","doi-asserted-by":"publisher","first-page":"4233","DOI":"10.1021\/acs.jmedchem.8b01469","volume":"62","author":"S Tadesse","year":"2019","unstructured":"Tadesse S, Caldon EC, Tilley W, Wang S. Cyclin-dependent kinase 2 inhibitors in cancer therapy: an update. J Med Chem. 2019;62(9):4233\u201351. https:\/\/doi.org\/10.1021\/acs.jmedchem.8b01469.","journal-title":"J Med Chem"},{"issue":"17","key":"569_CR44","first-page":"2435","volume":"18","author":"RY Liu","year":"2014","unstructured":"Liu RY, Li JP. Saikosaponin-d inhibits proliferation of human undifferentiated thyroid carcinoma cells through induction of apoptosis and cell cycle arrest. Eur Rev Med Pharmacol Sci. 2014;18(17):2435\u201343.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"5","key":"569_CR45","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1038\/s41423-020-00630-3","volume":"18","author":"D Bertheloot","year":"2021","unstructured":"Bertheloot D, Latz E, Franklin BS. Necroptosis, pyroptosis and apoptosis: an intricate game of cell death. Cell Mol Immunol. 2021;18(5):1106\u201321. https:\/\/doi.org\/10.1038\/s41423-020-00630-3.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"569_CR46","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s13045-022-01392-3","volume":"15","author":"X Tong","year":"2022","unstructured":"Tong X, Tang R, Xiao M, Xu J, Wang W, Zhang B, Liu J, Yu X, Shi S. Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research. J Hematol Oncol. 2022;15(1):174. https:\/\/doi.org\/10.1186\/s13045-022-01392-3.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"569_CR47","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.bpj.2012.12.010","volume":"104","author":"S Bleicken","year":"2013","unstructured":"Bleicken S, Wagner C, Garc\u00eda-S\u00e1ez AJ. Mechanistic differences in the membrane activity of Bax and Bcl-xL correlate with their opposing roles in apoptosis. Biophys J. 2013;104(2):421\u201331. https:\/\/doi.org\/10.1016\/j.bpj.2012.12.010.","journal-title":"Biophys J"},{"issue":"4","key":"569_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.107959","volume":"32","author":"NM de Vasconcelos","year":"2020","unstructured":"de Vasconcelos NM, Van Opdenbosch N, Van Gorp H, Mart\u00edn-P\u00e9rez R, Zecchin A, Vandenabeele P, Lamkanfi M. An Apoptotic caspase network safeguards cell death induction in pyroptotic macrophages. Cell Rep. 2020;32(4): 107959. https:\/\/doi.org\/10.1016\/j.celrep.2020.107959.","journal-title":"Cell Rep"},{"key":"569_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.fct.2023.113815","volume":"177","author":"TT Tang","year":"2023","unstructured":"Tang TT, Jiang L, Zhong Q, Ni ZJ, Thakur K, Khan MR, Wei ZJ. Saikosaponin D exerts cytotoxicity on human endometrial cancer ishikawa cells by inducing apoptosis and inhibiting metastasis through MAPK pathways. Food Chem Toxicol. 2023;177: 113815. https:\/\/doi.org\/10.1016\/j.fct.2023.113815.","journal-title":"Food Chem Toxicol"},{"issue":"17\u201318","key":"569_CR50","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1101\/gad.315739.118","volume":"32","author":"G Wang","year":"2018","unstructured":"Wang G, Zhao D, Spring DJ, DePinho RA. Genetics and biology of prostate cancer. Genes Dev. 2018;32(17\u201318):1105\u201340. https:\/\/doi.org\/10.1101\/gad.315739.118.","journal-title":"Genes Dev"},{"issue":"1","key":"569_CR51","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s004410000196","volume":"301","author":"EM Bruckheimer","year":"2000","unstructured":"Bruckheimer EM, Kyprianou N. Apoptosis in prostate carcinogenesis. A growth regulator and a therapeutic target. Cell Tissue Res. 2000;301(1):153\u201362. https:\/\/doi.org\/10.1007\/s004410000196.","journal-title":"Cell Tissue Res"},{"key":"569_CR52","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3389\/fcell.2015.00024","volume":"3","author":"WJ Davis","year":"2015","unstructured":"Davis WJ, Lehmann PZ, Li W. Nuclear PI3K signaling in cell growth and tumorigenesis. Front Cell Dev Biol. 2015;3:24. https:\/\/doi.org\/10.3389\/fcell.2015.00024.","journal-title":"Front Cell Dev Biol"},{"issue":"11","key":"569_CR53","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1080\/13543784.2019.1676726","volume":"28","author":"M Shariati","year":"2019","unstructured":"Shariati M, Meric-Bernstam F. Targeting AKT for cancer therapy. Expert Opin Investig Drugs. 2019;28(11):977\u201388. https:\/\/doi.org\/10.1080\/13543784.2019.1676726.","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"569_CR54","doi-asserted-by":"publisher","first-page":"9674","DOI":"10.1038\/s41598-023-33792-x","volume":"13","author":"P Niu","year":"2023","unstructured":"Niu P, Liu F, Lei F, Peng J, Wang Y, Zhao J, Gao Z, Gao Q, Gu J. Breviscapine regulates the proliferation, migration, invasion, and apoptosis of colorectal cancer cells via the PI3K\/AKT pathway. Sci Rep. 2023;13(1):9674. https:\/\/doi.org\/10.1038\/s41598-023-33792-x.","journal-title":"Sci Rep"},{"issue":"1","key":"569_CR55","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","volume":"6","author":"Y He","year":"2021","unstructured":"He Y, Sun MM, Zhang GG, Yang J, Chen KS, Xu WW, Li B. Targeting PI3K\/Akt signal transduction for cancer therapy. Signal Transduct Target Ther. 2021;6(1):425. https:\/\/doi.org\/10.1038\/s41392-021-00828-5.","journal-title":"Signal Transduct Target Ther"},{"key":"569_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.fct.2019.110863","volume":"135","author":"YS Won","year":"2020","unstructured":"Won YS, Seo KI. Lupiwighteone induces caspase-dependent and -independent apoptosis on human breast cancer cells via inhibiting PI3K\/Akt\/mTOR pathway. Food Chem Toxicol. 2020;135: 110863. https:\/\/doi.org\/10.1016\/j.fct.2019.110863.","journal-title":"Food Chem Toxicol"},{"issue":"1","key":"569_CR57","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1152\/physrev.1999.79.1.143","volume":"79","author":"C Widmann","year":"1999","unstructured":"Widmann C, Gibson S, Jarpe MB, Johnson GL. Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol Rev. 1999;79(1):143\u201380. https:\/\/doi.org\/10.1152\/physrev.1999.79.1.143.","journal-title":"Physiol Rev"},{"issue":"6","key":"569_CR58","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.3390\/ijms21061913","volume":"21","author":"A Mart\u00ednez-Lim\u00f3n","year":"2020","unstructured":"Mart\u00ednez-Lim\u00f3n A, Joaquin M, Caballero M, Posas F, de Nadal E. The p38 pathway: from biology to cancer therapy. Int J Mol Sci. 2020;21(6):1913. https:\/\/doi.org\/10.3390\/ijms21061913.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"569_CR59","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1042\/bj20100323","volume":"429","author":"A Cuadrado","year":"2010","unstructured":"Cuadrado A, Nebreda AR. Mechanisms and functions of p38 MAPK signalling. Biochem J. 2010;429(3):403\u201317. https:\/\/doi.org\/10.1042\/bj20100323.","journal-title":"Biochem J"},{"issue":"2","key":"569_CR60","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.3892\/mmr.2020.11155","volume":"22","author":"R Fu","year":"2020","unstructured":"Fu R, Zhang L, Li Y, Li B, Ming Y, Li Z, Xing H, Chen J. Saikosaponins D inhibits autophagosome-lysosome fusion and induces autophagy-independent apoptosis in MDA-MB-231 breast cancer cells. Mol Med Rep. 2020;22(2):1026\u201334. https:\/\/doi.org\/10.3892\/mmr.2020.11155.","journal-title":"Mol Med Rep"},{"issue":"4","key":"569_CR61","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s12272-013-0044-3","volume":"36","author":"YM Kim","year":"2013","unstructured":"Kim YM, Ku MJ, Son YJ, Yun JM, Kim SH, Lee SY. Anti-metastatic effect of cantharidin in A549 human lung cancer cells. Arch Pharm Res. 2013;36(4):479\u201384. https:\/\/doi.org\/10.1007\/s12272-013-0044-3.","journal-title":"Arch Pharm Res"},{"issue":"5","key":"569_CR62","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.cell.2009.11.007","volume":"139","author":"JP Thiery","year":"2009","unstructured":"Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139(5):871\u201390. https:\/\/doi.org\/10.1016\/j.cell.2009.11.007.","journal-title":"Cell"},{"issue":"6","key":"569_CR63","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.ccr.2012.11.009","volume":"22","author":"T Brabletz","year":"2012","unstructured":"Brabletz T. EMT and MET in metastasis: where are the cancer stem cells? Cancer Cell. 2012;22(6):699\u2013701. https:\/\/doi.org\/10.1016\/j.ccr.2012.11.009.","journal-title":"Cancer Cell"},{"issue":"12","key":"569_CR64","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/j.ejca.2015.04.021","volume":"51","author":"NM Ghahhari","year":"2015","unstructured":"Ghahhari NM, Babashah S. Interplay between microRNAs and WNT\/\u03b2-catenin signalling pathway regulates epithelial-mesenchymal transition in cancer. Eur J Cancer. 2015;51(12):1638\u201349. https:\/\/doi.org\/10.1016\/j.ejca.2015.04.021.","journal-title":"Eur J Cancer"},{"issue":"9","key":"569_CR65","doi-asserted-by":"publisher","first-page":"6785","DOI":"10.1007\/s00432-023-04614-4","volume":"149","author":"S Li","year":"2023","unstructured":"Li S, Zhang H, Liu J, Shang G. Targeted therapy for osteosarcoma: a review. J Cancer Res Clin Oncol. 2023;149(9):6785\u201397. https:\/\/doi.org\/10.1007\/s00432-023-04614-4.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"569_CR66","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s40744-016-0046-y","volume":"3","author":"RA Durfee","year":"2016","unstructured":"Durfee RA, Mohammed M, Luu HH. Review of osteosarcoma and current management. Rheumatol Ther. 2016;3(2):221\u201343. https:\/\/doi.org\/10.1007\/s40744-016-0046-y.","journal-title":"Rheumatol Ther"},{"issue":"9","key":"569_CR67","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.21873\/anticanres.10982","volume":"36","author":"S Osasan","year":"2016","unstructured":"Osasan S, Zhang M, Shen F, Paul PJ, Persad S, Sergi C. Osteogenic sarcoma: a 21st century review. Anticancer Res. 2016;36(9):4391\u20138. https:\/\/doi.org\/10.21873\/anticanres.10982.","journal-title":"Anticancer Res"},{"issue":"4","key":"569_CR68","first-page":"2070","volume":"11","author":"T Gao","year":"2019","unstructured":"Gao T, Zhao P, Yu X, Cao S, Zhang B, Dai M. Use of Saikosaponins D and JNK inhibitor SP600125, alone or in combination, inhibits malignant properties of human osteosarcoma U2 cells. Am J Transl Res. 2019;11(4):2070\u201380.","journal-title":"Am J Transl Res"},{"issue":"4","key":"569_CR69","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.bbrc.2016.05.017","volume":"474","author":"D Zhong","year":"2016","unstructured":"Zhong D, Zhang HJ, Jiang YD, Wu P, Qi H, Cai C, Zheng SB, Dang Q. Saikosaponin-d: a potential chemotherapeutics in castration resistant prostate cancer by suppressing cancer metastases and cancer stem cell phenotypes. Biochem Biophys Res Commun. 2016;474(4):722\u20139. https:\/\/doi.org\/10.1016\/j.bbrc.2016.05.017.","journal-title":"Biochem Biophys Res Commun"},{"key":"569_CR70","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21093233","author":"K Bukowski","year":"2020","unstructured":"Bukowski K, Kciuk M, Kontek R. Mechanisms of multidrug resistance in cancer chemotherapy. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21093233.","journal-title":"Int J Mol Sci"},{"key":"569_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2019.100645","volume":"46","author":"YG Assaraf","year":"2019","unstructured":"Assaraf YG, Brozovic A, Gon\u00e7alves AC, Jurkovicova D, Lin\u0113 A, Machuqueiro M, Saponara S, Sarmento-Ribeiro AB, Xavier CPR, Vasconcelos MH. The multi-factorial nature of clinical multidrug resistance in cancer. Drug Resist Update. 2019;46: 100645. https:\/\/doi.org\/10.1016\/j.drup.2019.100645.","journal-title":"Drug Resist Update"},{"key":"569_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2021.100796","volume":"59","author":"R Nussinov","year":"2021","unstructured":"Nussinov R, Tsai CJ, Jang H. Anticancer drug resistance: an update and perspective. Drug Resist Updates Rev Comment Antimicrob Anticancer Chemother. 2021;59: 100796. https:\/\/doi.org\/10.1016\/j.drup.2021.100796.","journal-title":"Drug Resist Updates Rev Comment Antimicrob Anticancer Chemother"},{"issue":"1","key":"569_CR73","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s12943-022-01680-z","volume":"21","author":"Z Liu","year":"2022","unstructured":"Liu Z, Zou H, Dang Q, Xu H, Liu L, Zhang Y, Lv J, Li H, Zhou Z, Han X. Biological and pharmacological roles of m6A modifications in cancer drug resistance. Mol Cancer. 2022;21(1):220. https:\/\/doi.org\/10.1186\/s12943-022-01680-z.","journal-title":"Mol Cancer"},{"key":"569_CR74","doi-asserted-by":"publisher","first-page":"12385","DOI":"10.2147\/CMAR.S274599","volume":"12","author":"WJ Huang","year":"2020","unstructured":"Huang WJ, Ruan S, Wen F, Lu XN, Gu SP, Chen XX, Liu M, Shu P. Multidrug resistance of gastric cancer: the mechanisms and Chinese medicine reversal agents. Cancer Manag Res. 2020;12:12385\u201394. https:\/\/doi.org\/10.2147\/CMAR.S274599.","journal-title":"Cancer Manag Res"},{"issue":"3","key":"569_CR75","doi-asserted-by":"publisher","first-page":"129","DOI":"10.4103\/0973-1482.19585","volume":"1","author":"S Girdhani","year":"2005","unstructured":"Girdhani S, Bhosle SM, Thulsidas SA, Kumar A, Mishra KP. Potential of radiosensitizing agents in cancer chemo-radiotherapy. J Cancer Res Ther. 2005;1(3):129\u201331. https:\/\/doi.org\/10.4103\/0973-1482.19585.","journal-title":"J Cancer Res Ther"},{"issue":"7","key":"569_CR76","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1080\/17460441.2019.1613370","volume":"14","author":"N Albadari","year":"2019","unstructured":"Albadari N, Deng S, Li W. The transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy. Expert Opin Drug Discov. 2019;14(7):667\u201382. https:\/\/doi.org\/10.1080\/17460441.2019.1613370.","journal-title":"Expert Opin Drug Discov"},{"key":"569_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2021.145796","volume":"798","author":"M Rashid","year":"2021","unstructured":"Rashid M, Zadeh LR, Baradaran B, Molavi O, Ghesmati Z, Sabzichi M, Ramezani F. Up-down regulation of HIF-1\u03b1 in cancer progression. Gene. 2021;798: 145796. https:\/\/doi.org\/10.1016\/j.gene.2021.145796.","journal-title":"Gene"},{"issue":"11","key":"569_CR78","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1002\/1878-0261.13508","volume":"17","author":"OD Biziotis","year":"2023","unstructured":"Biziotis OD, Tsakiridis EE, Ali A, Ahmadi E, Wu J, Wang S, Mekhaeil B, Singh K, Menjolian G, Farrell T, Abdulkarim B, Sur RK, Mesci A, Ellis P, Berg T, Bramson JL, Muti P, Steinberg GR, Tsakiridis T. Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non-small cell lung cancer (NSCLC) through inhibition of HIF-1\u03b1. Mol Oncol. 2023;17(11):2235\u201356. https:\/\/doi.org\/10.1002\/1878-0261.13508.","journal-title":"Mol Oncol"},{"issue":"13","key":"569_CR79","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.3390\/cancers14133273","volume":"14","author":"CW Song","year":"2022","unstructured":"Song CW, Kim H, Cho H, Kim MS, Paek SH, Park HJ, Griffin RJ, Terezakis S, Cho LC. HIF-1\u03b1 inhibition improves anti-tumor immunity and promotes the efficacy of stereotactic ablative radiotherapy (SABR). Cancers. 2022;14(13):3273. https:\/\/doi.org\/10.3390\/cancers14133273.","journal-title":"Cancers"},{"issue":"54","key":"569_CR80","doi-asserted-by":"publisher","first-page":"7508","DOI":"10.1038\/sj.onc.1210556","volume":"26","author":"H Harada","year":"2007","unstructured":"Harada H, Kizaka-Kondoh S, Li G, Itasaka S, Shibuya K, Inoue M, Hiraoka M. Significance of HIF-1-active cells in angiogenesis and radioresistance. Oncogene. 2007;26(54):7508\u201316. https:\/\/doi.org\/10.1038\/sj.onc.1210556.","journal-title":"Oncogene"},{"key":"569_CR81","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/1471-2407-7-213","volume":"7","author":"A Staab","year":"2007","unstructured":"Staab A, Loeffler J, Said HM, Diehlmann D, Katzer A, Beyer M, Fleischer M, Schwab F, Baier K, Einsele H, Flentje M, Vordermark D. Effects of HIF-1 inhibition by chetomin on hypoxia-related transcription and radiosensitivity in HT 1080 human fibrosarcoma cells. BMC Cancer. 2007;7:213. https:\/\/doi.org\/10.1186\/1471-2407-7-213.","journal-title":"BMC Cancer"},{"issue":"1","key":"569_CR82","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1159\/000356648","volume":"33","author":"BF Wang","year":"2014","unstructured":"Wang BF, Wang XJ, Kang HF, Bai MH, Guan HT, Wang ZW, Zan Y, Song LQ, Min WL, Lin S, Cheng YA. Saikosaponin-D enhances radiosensitivity of hepatoma cells under hypoxic conditions by inhibiting hypoxia-inducible factor-1\u03b1. Cell Physiol Biochem. 2014;33(1):37\u201351. https:\/\/doi.org\/10.1159\/000356648.","journal-title":"Cell Physiol Biochem"},{"key":"569_CR83","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/1472-6882-13-263","volume":"13","author":"BF Wang","year":"2013","unstructured":"Wang BF, Dai ZJ, Wang XJ, Bai MH, Lin S, Ma HB, Wang YL, Song LQ, Ma XL, Zan Y, Min WL, Cheng YA. Saikosaponin-d increases the radiosensitivity of smmc-7721 hepatocellular carcinoma cells by adjusting the g0\/g1 and g2\/m checkpoints of the cell cycle. BMC Complement Altern Med. 2013;13:263. https:\/\/doi.org\/10.1186\/1472-6882-13-263.","journal-title":"BMC Complement Altern Med"},{"issue":"20","key":"569_CR84","doi-asserted-by":"publisher","first-page":"4947","DOI":"10.7150\/jca.30286","volume":"10","author":"YD Tian","year":"2019","unstructured":"Tian YD, Lin S, Yang PT, Bai MH, Jin YY, Min WL, Ma HB, Wang BF. Saikosaponin-d increases the radiosensitivity of hepatoma cells by adjusting cell autophagy. J Cancer. 2019;10(20):4947\u201353. https:\/\/doi.org\/10.7150\/jca.30286.","journal-title":"J Cancer"},{"issue":"29","key":"569_CR85","doi-asserted-by":"publisher","first-page":"18745","DOI":"10.1021\/acsomega.1c01795","volume":"6","author":"J Hu","year":"2021","unstructured":"Hu J, Li P, Shi B, Tie J. Effects and mechanisms of saikosaponins d improving the sensitivity of human gastric cancer cells to cisplatin. ACS Omega. 2021;6(29):18745\u201355. https:\/\/doi.org\/10.1021\/acsomega.1c01795.","journal-title":"ACS Omega"},{"issue":"26","key":"569_CR86","doi-asserted-by":"publisher","first-page":"6666","DOI":"10.7150\/jca.30361","volume":"10","author":"JC Tang","year":"2019","unstructured":"Tang JC, Long F, Zhao J, Hang J, Ren YG, Chen JY, Mu B. The effects and mechanisms by which saikosaponin-d enhances the sensitivity of human non-small cell lung cancer cells to gefitinib. J Cancer. 2019;10(26):6666\u201372. https:\/\/doi.org\/10.7150\/jca.30361.","journal-title":"J Cancer"},{"issue":"10","key":"569_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2022.e11171","volume":"8","author":"C Pilotto Heming","year":"2022","unstructured":"Pilotto Heming C, Muriithi W, Wanjiku Macharia L, Niemeyer Filho P, Moura-Neto V, Aran V. P-glycoprotein and cancer: what do we currently know? Heliyon. 2022;8(10): e11171. https:\/\/doi.org\/10.1016\/j.heliyon.2022.e11171.","journal-title":"Heliyon"},{"key":"569_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2023.108488","volume":"249","author":"J Dong","year":"2023","unstructured":"Dong J, Yuan L, Hu C, Cheng X, Qin JJ. Strategies to overcome cancer multidrug resistance (MDR) through targeting P-glycoprotein (ABCB1): an updated review. Pharmacol Ther. 2023;249: 108488. https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108488.","journal-title":"Pharmacol Ther"},{"issue":"9","key":"569_CR89","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.3390\/ijms21093233","volume":"21","author":"K Bukowski","year":"2020","unstructured":"Bukowski K, Kciuk M, Kontek R. Mechanisms of multidrug resistance in cancer chemotherapy. Int J Mol Sci. 2020;21(9):3233. https:\/\/doi.org\/10.3390\/ijms21093233.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"569_CR90","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/med.21739","volume":"41","author":"H Zhang","year":"2021","unstructured":"Zhang H, Xu H, Ashby CR Jr, Assaraf YG, Chen ZS, Liu HM. Chemical molecular-based approach to overcome multidrug resistance in cancer by targeting P-glycoprotein (P-gp). Med Res Rev. 2021;41(1):525\u201355. https:\/\/doi.org\/10.1002\/med.21739.","journal-title":"Med Res Rev"},{"issue":"5","key":"569_CR91","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3892\/ijo.2023.5567","volume":"63","author":"Y Tian","year":"2023","unstructured":"Tian Y, Lei Y, Wang Y, Lai J, Wang J, Xia F. Mechanism of multidrug resistance to chemotherapy mediated by P-glycoprotein (review). Int J Oncol. 2023;63(5):119. https:\/\/doi.org\/10.3892\/ijo.2023.5567.","journal-title":"Int J Oncol"},{"issue":"3","key":"569_CR92","doi-asserted-by":"publisher","first-page":"269","DOI":"10.5603\/PJNNS.a2021.0024","volume":"55","author":"AE \u0141aba","year":"2021","unstructured":"\u0141aba AE, Zi\u00f3\u0142kowski P. Trends in glioblastoma treatment research: an analysis of clinical trials and literature. Neurol Neurochir Pol. 2021;55(3):269\u201380. https:\/\/doi.org\/10.5603\/PJNNS.a2021.0024.","journal-title":"Neurol Neurochir Pol"},{"issue":"6","key":"569_CR93","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2217\/bmm-2021-0113","volume":"15","author":"E Mikhael","year":"2021","unstructured":"Mikhael E, Kourie HR. Targeting glioblastoma: from dream to reality. Biomark Med. 2021;15(6):385\u20138. https:\/\/doi.org\/10.2217\/bmm-2021-0113.","journal-title":"Biomark Med"},{"key":"569_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrep.2022.101342","volume":"32","author":"J Liang","year":"2022","unstructured":"Liang J, Sun J, Liu A, Chen L, Ma X, Liu X, Zhang C. Saikosaponins D improves chemosensitivity of glioblastoma by reducing the its stemness maintenance. Biochem Biophys Rep. 2022;32: 101342. https:\/\/doi.org\/10.1016\/j.bbrep.2022.101342.","journal-title":"Biochem Biophys Rep"},{"key":"569_CR95","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.semcancer.2021.04.003","volume":"85","author":"J Jiang","year":"2022","unstructured":"Jiang J. Hedgehog signaling mechanism and role in cancer. Semin Cancer Biol. 2022;85:107\u201322. https:\/\/doi.org\/10.1016\/j.semcancer.2021.04.003.","journal-title":"Semin Cancer Biol"},{"issue":"14","key":"569_CR96","doi-asserted-by":"publisher","first-page":"5549","DOI":"10.1074\/jbc.RA118.007018","volume":"294","author":"Z Zhang","year":"2019","unstructured":"Zhang Z, Zhan X, Kim B, Wu J. A proteomic approach identifies SAFB-like transcription modulator (SLTM) as a bidirectional regulator of GLI family zinc finger transcription factors. J Biol Chem. 2019;294(14):5549\u201361. https:\/\/doi.org\/10.1074\/jbc.RA118.007018.","journal-title":"J Biol Chem"},{"issue":"14","key":"569_CR97","doi-asserted-by":"publisher","first-page":"3410","DOI":"10.3390\/cancers13143410","volume":"13","author":"AN Sigafoos","year":"2021","unstructured":"Sigafoos AN, Paradise BD, Fernandez-Zapico ME. Hedgehog\/GLI signaling pathway: transduction, regulation, and implications for disease. Cancers. 2021;13(14):3410. https:\/\/doi.org\/10.3390\/cancers13143410.","journal-title":"Cancers"},{"issue":"24","key":"569_CR98","doi-asserted-by":"publisher","first-page":"20483","DOI":"10.1074\/jbc.M112.359299","volume":"287","author":"L Han","year":"2012","unstructured":"Han L, Pan Y, Wang B. Small ubiquitin-like modifier (SUMO) modification inhibits GLI2 protein transcriptional activity in vitro and in vivo. J Biol Chem. 2012;287(24):20483\u20139. https:\/\/doi.org\/10.1074\/jbc.M112.359299.","journal-title":"J Biol Chem"},{"issue":"4","key":"569_CR99","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.devcel.2016.09.014","volume":"39","author":"G Ma","year":"2016","unstructured":"Ma G, Li S, Han Y, Li S, Yue T, Wang B, Jiang J. Regulation of smoothened trafficking and hedgehog signaling by the SUMO pathway. Dev Cell. 2016;39(4):438\u201351. https:\/\/doi.org\/10.1016\/j.devcel.2016.09.014.","journal-title":"Dev Cell"},{"issue":"7","key":"569_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2018.e00709","volume":"4","author":"TM Hoard","year":"2018","unstructured":"Hoard TM, Yang XP, Jetten AM, ZeRuth GT. PIAS-family proteins negatively regulate Glis3 transactivation function through SUMO modification in pancreatic \u03b2 cells. Heliyon. 2018;4(7): e00709. https:\/\/doi.org\/10.1016\/j.heliyon.2018.e00709.","journal-title":"Heliyon"},{"key":"569_CR101","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ejps.2019.04.011","volume":"134","author":"NM Kocaturk","year":"2019","unstructured":"Kocaturk NM, Akkoc Y, Kig C, Bayraktar O, Gozuacik D, Kutlu O. Autophagy as a molecular target for cancer treatment. Eur J Pharm Sci. 2019;134:116\u201337. https:\/\/doi.org\/10.1016\/j.ejps.2019.04.011.","journal-title":"Eur J Pharm Sci"},{"issue":"16","key":"569_CR102","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1002\/cncr.31335","volume":"124","author":"AV Onorati","year":"2018","unstructured":"Onorati AV, Dyczynski M, Ojha R, Amaravadi RK. Targeting autophagy in cancer. Cancer. 2018;124(16):3307\u201318. https:\/\/doi.org\/10.1002\/cncr.31335.","journal-title":"Cancer"},{"issue":"4","key":"569_CR103","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/s41418-019-0292-y","volume":"26","author":"F Nazio","year":"2019","unstructured":"Nazio F, Bordi M, Cianfanelli V, Locatelli F, Cecconi F. Autophagy and cancer stem cells: molecular mechanisms and therapeutic applications. Cell Death Differ. 2019;26(4):690\u2013702. https:\/\/doi.org\/10.1038\/s41418-019-0292-y.","journal-title":"Cell Death Differ"},{"issue":"4","key":"569_CR104","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.cell.2011.10.026","volume":"147","author":"N Mizushima","year":"2011","unstructured":"Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues. Cell. 2011;147(4):728\u201341. https:\/\/doi.org\/10.1016\/j.cell.2011.10.026.","journal-title":"Cell"},{"key":"569_CR105","doi-asserted-by":"publisher","first-page":"5489553","DOI":"10.1155\/2022\/5489553","volume":"2022","author":"G Liu","year":"2022","unstructured":"Liu G, Guan Y, Liu Y, et al. Saikosaponins D inducing apoptosis and autophagy through the activation of endoplasmic reticulum stress in glioblastoma. Biomed Res Int. 2022;2022:5489553. https:\/\/doi.org\/10.1155\/2022\/5489553.","journal-title":"Biomed Res Int"},{"issue":"6","key":"569_CR106","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.7150\/ijms.53024","volume":"18","author":"B Wang","year":"2021","unstructured":"Wang B, Min W, Lin S, Song L, Yang P, Ma Q, Guo J. Saikosaponin-d increases radiation-induced apoptosis of hepatoma cells by promoting autophagy via inhibiting mTOR phosphorylation. Int J Med Sci. 2021;18(6):1465\u201373. https:\/\/doi.org\/10.7150\/ijms.53024.","journal-title":"Int J Med Sci"},{"issue":"5\u20136","key":"569_CR107","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.mam.2006.08.005","volume":"27","author":"EL Eskelinen","year":"2006","unstructured":"Eskelinen EL. Roles of LAMP-1 and LAMP-2 in lysosome biogenesis and autophagy. Mol Asp Med. 2006;27(5\u20136):495\u2013502. https:\/\/doi.org\/10.1016\/j.mam.2006.08.005.","journal-title":"Mol Asp Med"},{"issue":"18","key":"569_CR108","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1016\/j.bmcl.2015.07.053","volume":"25","author":"DQ Li","year":"2015","unstructured":"Li DQ, Wu J, Liu LY, Wu YY, Li LZ, Huang XX, Liu QB, Yang JY, Song SJ, Wu CF. Cytotoxic triterpenoid glycosides (saikosaponins) from the roots of Bupleurum Chinense. Bioorg Med Chem Lett. 2015;25(18):3887\u201392. https:\/\/doi.org\/10.1016\/j.bmcl.2015.07.053.","journal-title":"Bioorg Med Chem Lett"},{"issue":"1","key":"569_CR109","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2174\/1871520619666181224121004","volume":"19","author":"S Gezici","year":"2019","unstructured":"Gezici S, \u015eekero\u011flu N. Current perspectives in the application of medicinal plants against cancer: novel therapeutic agents. Anticancer Agents Med Chem. 2019;19(1):101\u201311. https:\/\/doi.org\/10.2174\/1871520619666181224121004.","journal-title":"Anticancer Agents Med Chem"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-024-00569-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-024-00569-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-024-00569-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T07:03:15Z","timestamp":1722495795000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-024-00569-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,4]]},"references-count":109,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["569"],"URL":"https:\/\/doi.org\/10.1007\/s43440-024-00569-6","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,4]]},"assertion":[{"value":"16 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}